- Home
- » Tags
- » Glibenclamide
Top View
- Differential Interactions of Nateglinide and Repaglinide on the Human -Cell Sulphonylurea Receptor 1
- Interactions with Experimental COVID-19 Therapies
- A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events a Comparison of Glyburide with Other Secretagogues and with Insulin
- Glibenclamide/Glipizide 441
- In Vitro to in Vivo Extrapolation for Drug-Induced Liver Injury Using a Pair Ranking Method
- Comparison of Gliclazide and Glibenclamide Treatment in Non-Insulin-Dependent Diabetes
- Chronic Exposure to Tolbutamide and Glibenclamide Impairs Insulin Secretion but Not Transcription of K-ATP Channel Components
- Daonil Tablets Must Be Swallowed Whole with Sufficient Amounts of Liquid, E.G
- Incidence of Hypoglycemia and Other Side Effects in Patients of Type 2 Diabetes Mellitus Treated with Glimepiride Versus Glibenclamide
- Possible Pharmacological Interactions in Hypertensive And/Or Diabetic Elderly in Family Health Units at Blumenau (SC)
- Information for the User Ponstan 250 Mg Capsules Mefenamic Acid Read All of This Leaflet Carefully Before You S
- Comparison of the Effects of Three Insulinotropic Drugs on Plasma Insulin Levels After a Standard Meal
- Articles Mortality Risk Among Sulfonylureas: a Systematic Review
- Glibenclamide-Associated Hypoglycaemia: a Report on 57 Cases
- Data Sheet Template
- Flufenamic Acid Inhibits Secondary Hemorrhage and BSCB Disruption
- Hypoglycaemic Effect of Glibenclamide: a Critical Study on the Basis of Creatinine and Lipid Peroxidation Status of Streptozotocin-Induced Diabetic Rat
- Glipizide, Gliquidone, and Glimepiride, Which Vary in Duration of Action
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Promise of the NLRP3 Inflammasome Inhibitors in in Vivo Disease Models
- [3H]Glibenclamide-Binding Protein, a Putative Neuronal
- Prandin, INN-Repaglinide
- Drug Interactions Involving the New Second- and Third- Generation Antiepileptic Drugs
- Title: Glyburide, Gliclazide Or Glimepiride in the Elderly Date: 18 April, 2007 Context and Policy Issues: Type 2 Diabetes Is
- Evaluation of the Anti-Diabetic Effect Of
- Safety of Type 2 Diabetes Treatment with Repaglinide Compared with Glibenclamide in Elderly People a Randomized, Open-Label, Two-Period, Cross-Over Trial
- Repurposing of FDA-Approved Nsaids for DPP-4 Inhibition As an Alternative for Diabetes Mellitus Treatment: Computational and in Vitro Study
- Glibenclamide, Glimepiride, and Gliclazide) on Proliferation and Migration of Vascular Smooth Muscle Cells
- Comparative Study Between Glimepiride and Glibenclamide in the Treatment of Type 2 Diabetic Patients in Al-Yarmouk Hospital
- Glibenclamide but Not Other Sulphonylureas Stimulates Release of Neuropeptide Y from Perifused Rat Islets and Hamster Insulinoma Cells
- Nateglinide with Glibenclamide Examination Using the Respiratory Quotient (RQ)
- Antiepileptic Drug Interactions
- Improved Prandial Glucose Control with Lower Risk of Hypoglycemia with Nateglinide Than with Glibenclamide in Patients with Matu